BANVİT BANDIRMA VİTAMİNLİ YEM SANAYİ ANONİM ŞİRKETİ
01 JAN 2026 – 30 SEP 2026 INTERIM PERIOD ACTIVITY REPORT

TABLE OF CONTENTS

A. General Information

1. Reporting Period
2. Information Regarding the Company
3. Shareholding Structure and Capital Distribution
4. Explanations on Privileged Shares and Voting Rights
5. Information on the Members of the Board of Directors and Senior Executives
6. Employee and Worker Movements, Collective Bargaining Practices, and Rights and Benefits Provided to Employees and Workers
7. Corporate Governance Principles Compliance Report
8. Amendments Made to the Articles of Association

B. Financial Rights Provided to Members of the Board of Directors and Executives

1. Total Amount of Financial Benefits Such as Attendance Fees, Salaries, Bonuses, Premiums, and Profit Shares
2. Information on Allowances, Travel, Accommodation and Representation Expenses, In-kind and Cash Benefits, Insurance, and Similar Guarantees

C. Research and Development Activities

D. Company Activities and Significant Developments Related to Activities

1. Investment Activities
2. Internal Control System and Internal Audit Activities
3. Direct and Indirect Subsidiaries

E. Financial Position

1. Summary of Financial Statements
2. Key Financial Ratios
3. Development of Financing Resources and Policies Implemented by the Company Within This Framework
4. Nature and Amount of Capital Market Instruments Issued
5. General Assembly
6. Dividend Distribution
7. The Sector in Which the Company Operates and Its Position Within the Sector
8. Incentives
9. Development of the Company
10. Developments in Sales

F. Risk Management

1. Corporate Risk Management
2. Early Detection of Risk Committee

G. Other Matters

1. Organizational Structure
2. Sustainability Principles
3. Significant Developments
4. Significant Developments Occurring After the Reporting Period

H. Investor Relations

A. General Information

1) Reporting Period

01.01.2026 – 30.09.2026

2) Information Regarding the Company

Trade Name:	Banvit Bandırma Vitaminli Yem Sanayi A.Ş.
Trade Registry Number:	4153
Tax Office:	Bandırma
Tax Identification Number:	1400036590
Registered Office Address:	Ömerli Mah. Ömerli Sok. No: 2/8 A Bandırma- Balıkesir
Telephone and Fax:	Tel: (0266) 733 86 00 Pbx | Faks: (0850) 2001052
Website:	www.banvitas.com
Registered Capital Ceiling:	8,000,000,000 TRY
Paid-in/Issued Capital:	100,023,579 TRY

3) Shareholding Structure and Capital Distribution

Shareholdes	Number of Shares	%
BRF GMBH	55,036,207.82	55.02
QATAR HOLDİNG LLC	36,690,804.00	36.68
Published Traded	8,296,567.18	8.30
Total	100,023,579.00	100.00

There has been no change in the direct shareholding structure and capital distribution during the period.

4) Explanations on Privileged Shares and Voting Rights

There are no privileged shares in the Company's capital, and each shareholder is entitled to one (1) voting right per share.

5) Information on the Members of the Board of Directors and Senior Executives

In accordance with the provisions of the Turkish Commercial Code ("TCC") and the relevant regulations, as well as the Company's Articles of Association, the election of the members of the Board of Directors is carried out by the General Assembly. In cases where changes occur in the composition of the Board of Directors during the period, elections are conducted in line with the provisions of the TCC and the Company's Articles of Association, and such changes are submitted to the approval of the General Assembly. Any changes made during the period are effected by a resolution of the Board of Directors and are presented for approval at the next Ordinary General Assembly meeting.

Pursuant to the provisions of the Turkish Commercial Code and the Capital Markets Law, at the Ordinary General Assembly Meeting held on May 8, 2026 and registered with the Bandırma Trade Registry Office on May 18, 2026, eight (8) members of the Board of Directors, including

three (3) independent members, were elected by the General Assembly to serve a two-year term of office, in accordance with Article 8 of the Company's Articles of Association.

Members of the Board of Directors in Office as of Sep 30, 2026:

Name	Position	Term of Office
Fabio Luis Mendes Mariano	Chairman of the Board	08.05.2026 – 08.05.2028
Heraldo Geres	Deputy Chairman of the Board	08.05.2026 – 08.05.2028
Tang David	Member of the Board	08.05.2026 – 08.05.2028
Davide Luigi Vimercati	Member of the Board	08.05.2026 – 08.05.2028
Feras Abdulaziz M H Al-Naama	Member of the Board	08.05.2026 – 08.05.2028
Meral Kurdaş	Independent Member of the Board	08.05.2026 – 08.05.2028
Demet Özdemir	Independent Member of the Board	08.05.2026 – 08.05.2028
Bilgün Gürkan	Independent Member of the Board	08.05.2026 – 08.05.2028

Duties and Authorities of the Members of the Board of Directors

The Board of Directors performs and executes the duties assigned to it by the decisions of the General Assembly in accordance with the provisions of the Turkish Commercial Code (TCC), the Capital Markets Law, other applicable regulations, and Article 9 of the Company's Articles of Association.

Executive Management – As of Sep 30, 2026:

Name	Position	Date of Appointment
Tolga Gündüz	General Manager	16.10.2019
Levent Aytimur	Finance Director	09.01.2023
Nerdin Alp	Sales Director	06.04.2001
Atakan Sakin	Logistics Director	01.06.2022
Gökçen Aslan Özşar	Human Resources Director	27.09.2021
Miray Baran	Legal and Corporate Affairs Director	23.09.2021
Erdal Elmas	Agro Operations Director	01.02.2005
Özlem Kutluk	Business Planning and Development Director	12.01.2003
Paul George Caneja Sarmento	Quality Assurance and R&D Director	01.05.2025
Gökçe Uysal Kurer	Marketing and Corporate Communications Director	05.05.2025
Carlos Andre Fagundes	Production Director	01.03.2026

6) Employee and Worker Movements, Collective Bargaining Practices, and Rights and Benefits Provided to Employees and Workers

In the food industry line of business, the wages and fringe benefits of our blue-collar employees are subject to a collective bargaining agreement. Our white-collar employees are not covered by any collective agreement.

In addition to base salaries, our employees are provided with bonuses, marriage assistance, health insurance, profit-sharing payments from the Company's annual earnings, product assistance, meal allowance, and transportation allowance. Leave entitlements include annual paid leave, excuse leave, unpaid leave, as well as marriage leave, bereavement leave, pregnancy-related leave, maternity leave, and nursing leave.

Number of Employees of Banvit Bandırma Vitaminli Yem Sanayi A.Ş. as of Sep 30, 2026 and December 31, 2025:

	30.09.2026	31.12.2025
Blue Collar	3647	4095
White Collar	624	668
Total	**4271**	**4763**

7) Corporate Governance Principles Compliance Report

In accordance with the Capital Markets Board (CMB) resolution dated January 10, 2019 and numbered 2/49, the Company's Corporate Governance Compliance Report (URF), which presents the Company's compliance status with the mandatory and voluntary Corporate Governance Principles, and the Corporate Governance Information Form (KYBF), which provides information on the Company's current corporate governance practices, have been published on the Public Disclosure Platform (KAP) using the relevant templates and are publicly available at the following addresses:

https://www.kap.org.tr/tr/Bildirim/1396391 and https://www.kap.org.tr/tr/Bildirim/1396389.

Information regarding corporate governance can also be accessed through the following link: https://www.kap.org.tr/tr/cgif/4028e4a1415f4d990141601902e33250

In line with the CMB Communiqué on Corporate Governance (II-17.1) and the CMB Resolution No. 2/49 dated January 10, 2019, an integrated internal audit, internal control, and compliance management system has been established within the Company to ensure the sustainability of compliance with corporate governance principles.

The Internal Audit Department evaluates the Company's operations in terms of compliance with legislation, internal regulations, and ethical standards in line with the risk-based audit plan. Auditors operate in accordance with the principles of independence and objectivity. Findings and recommended actions are reported to the Audit Committee and the Board of Directors.

The Internal Control Department, which conducts its activities based on COSO standards, ensures segregation of duties on a process basis and assesses the effectiveness and efficiency of the Company's systems and processes through continuous monitoring and control testing. In order to eliminate existing or potential risk factors, the department coordinates with process owners to determine, implement, and sustain applicable action plans. These activities aim to ensure the effective functioning of the control environment within the Company.

The Compliance Department monitors adherence to legal regulations as well as to the Company's internal policies and procedures. Compliance risks are identified and monitored; regular training sessions are provided to employees, and secure and anonymous ethics channels are made available for reporting any potential misconduct or violations. All activities are regularly reported to senior management.

The Audit Committee evaluates the effectiveness of internal systems, monitors independent audit processes, and ensures the compliance of financial reporting with applicable regulations. The Committee convenes at least four times a year and reports its findings and recommendations to the Board of Directors.

This structure supports the sustainability of compliance with corporate governance principles, as well as transparency and accountability at the corporate level.

8) Amendments Made to the Articles of Association

No amendments were made to the Articles of Association during the reporting period.

B. Financial Rights Provided to Members of the Board of Directors and Senior Executives

1. **Total Amount of Financial Benefits Such as Attendance Fees, Salaries, Bonuses, Premiums, and Profit Shares Provided**

At the Ordinary General Assembly Meeting of the Company held on May 8, 2026, it was resolved not to pay any remuneration to the members of the Board of Directors, and to pay each Independent Member of the Board of Directors a gross monthly fee/attendance fee of TRY 144.499,00, starting from the month following the General Assembly and continuing until the next Ordinary General Assembly.

The salaries of senior executives are determined by the Company's Board of Directors. All senior executives are covered by private health insurance.

For the accounting period ended Sep 30, 2026, all benefits provided to senior executives are short-term benefits and include salaries, bonuses, and other payments.

Within the Company, including senior executives, non-union personnel receive performance-based additional payments.

Between 1 January 2026 and 30 September 2026, a total of TRY 114,740,395.34 was paid to senior executives, and TRY 6,140,855.51 was incurred as the employer's social security contribution (SGK). In addition, during the period from 1 January 2026 to 30 September 2026, a total of TRY 3,485,212.98 was paid as board remuneration fees to five independent members of the Board of Directors.

During the period, no loans were extended to any members of the Board of Directors or executives, no credit was made available to them directly or through third parties under the name of personal loans, and no guarantees such as sureties were provided in their favor.

No performance-based remuneration or incentive payment was made to the members of the Board of Directors during the reporting period.

2. **Information on the Total Amount of Allowances, Travel, Accommodation and Representation Expenses, In-kind and Cash Benefits, Insurances, and Similar Guarantees Provided**

The total amount of allowances, travel, accommodation and representation expenses, in-kind and cash benefits, and insurances provided to the members of the Board of Directors and senior executives during the period was TRY 3,499,939.52.

C. Research and Development Activities

In order to meet the demands and needs of our consumers, customers, and supplier companies in a creative, high-quality, practical, and delicious manner, our Company carries out research and development (R&D) activities focused on product development and the production of new products. In addition, our R&D efforts also cover areas such as identifying and implementing the most suitable and recyclable packaging for our products and ensuring effective waste management, thereby contributing to the Company's overall sustainability initiatives.

Within this scope, during the period from January 1, 2026 to 30 Sep, 2026,12 new products and14 new packaging types were developed. The Company also aims to increase the share of recyclable materials used in its packaging diversity. As a result of new product additions and discontinued items during the same period, the usage rate of recyclable packaging materials reached 93%.

D. Company Activities and Significant Developments Related to Activities

1) Investment Activities

As of Sep 30, 2026, the total investment expenditures of Banvit Bandırma Vitaminli Yem Sanayi A.Ş. amounted to TRY 282,708,973 (Sep 30, 2025: TRY 149,277,070).

2) Internal Control System and Internal Audit Activities

The Internal Audit Department provides the Board of Directors with independent and objective reasonable assurance regarding the Company's corporate governance processes. The Internal Audit activities aim to offer reasonable assurance to the Company's stakeholders, primarily its shareholders, concerning managerial accountability, the efficiency and effectiveness of business processes, the reliability of the financial reporting system, and the compliance of Company activities with laws and regulations. The Internal Audit activities are carried out in accordance with the "International Standards for the Professional Practice of Internal Auditing" established by the Institute of Internal Auditors (IIA). The Internal Audit Department operates in compliance with the "Banvit Internal Audit Charter" and monitors audit findings until the associated risks are fully mitigated.

The Internal Control Department carries out activities related to the early identification, assessment, and evaluation of risks that may affect the Company; the calculation of their impact and likelihood; and the management of these risks in line with the Company's corporate risk appetite. The department also ensures the reporting of risks, the implementation of necessary measures to reduce their impact and likelihood, and the establishment of effective internal control systems in this context. The Internal Control Department aims to ensure reliable financial reporting and effective risk management in accordance with the core components of internal control, which consist of control environment, risk assessment, control activities, information and communication, and monitoring.

3) Direct and Indirect Subsidiaries

As of Sep 30, 2026, Banvit Bandırma Vitaminli Yem Sanayi A.Ş. has no direct or indirect subsidiaries.

E. Financial Position

1) Summary of Financial Statements

The financial statements have been prepared in accordance with the financial reporting standards issued by the Capital Markets Board (CMB). In line with the Board of Directors' resolution No. 2021/22 dated October 6, 2021, the Company's first and third quarter interim financial statements are not subject to independent audit. A related material event disclosure was published on the Public Disclosure Platform (KAP) on October 7, 2021.

Summary Statement of Financial Position (Balance Sheet Summary)

	Not Reviewed	Audited
(TRY)	**Sep 30, 2026**	**December 31, 2025**
Current Assets	15,386,989,669	20,483,482,026
Non-Current Assets	10,347,088,060	10,825,505,025
Total Assets	**25,734,077,729**	**31,308,987,051**
Current Liabilities	11,652,939,635	15,599,882,166
Non-Current Liabilities	1,282,150,708	1,945,931,866
Equity	12,798,987,386	13,763,173,019
Total Liabilities and Equity	**25,734,077,729**	**31,308,987,051**

Summary Statement of Profit or Loss (Income Statement Summary)

	Not Reviewed	Not Reviewed
(TRY)	**January 1 – Sep 30, 2026**	**January 1 – Sep 30, 2025**
Sales	27,921,261,331	31,995,075,177
Gross Profit	1,184,471,546	1,624,746,870
EBITDA	129,100,479	126,110,693
Net Profit/(Loss)	-1,015,225,456	-1,254,106,166

The Company prepares its annual budget in accordance with its strategic objectives, and the budget is approved by the Board of Directors, During regular Board meetings, the Company's current position is reviewed, and its performance is compared with both the previous period and the approved budget targets,

2) Key Financial Ratios

(%)	January 1 – Sep 30, 2026	January 1 – Sep 30, 2025
Gross Profit Margin	4,24%	5,08%
EBITDA Margin	0,46%	0,39%
Net Profit/(Loss) Margin	-3,64%	-3,92%
Earnings/(Loss) per Share	(10,15) TL	(12,54) TL

3) Development of Financing Resources and the Policies Implemented by the Company Within This Framework

The Company continuously researches new financing alternatives suited to market conditions and evaluates the proposed options, Its borrowing policy is developed based on a strong equity structure and high cash generation capacity, Hedging methods and ratios to mitigate potential financial risks are determined within a defined model framework,

4) Nature and Amount of Capital Market Instruments Issued

No capital market instruments were issued during the period,

5) General Assembly

Pursuant to the resolution of our Board of Directors dated 30 March 2026, the 2025 Ordinary General Assembly Meeting was held on Friday, 8 May 2026, at 11:00 a.m. at the Banvit facilities located at Ömerli Mah. Ömerli Sok. No: 2/8A, Bandırma/Balıkesir, Türkiye.

Agenda of Banvit Bandırma Vitaminli Yem Sanayi A,Ş, 2025 Ordinary General Assembly Meeting

1. Opening of the meeting and establishment of the Meeting Presidency,
2. Reading and discussion of the Board of Directors' Annual Activity Report regarding the 2025 accounting period,
3. Reading of the summary of the Independent Auditor's Report regarding the 2025 accounting period,
4. Reading, discussion, and approval of the Financial Statements regarding the 2025 accounting period,
5. Separate discharge of the members of the Board of Directors for the Company's activities during the 2025 accounting period,
6. Determination of the number and terms of office of the members of the Board of Directors and election of the members of the Board of Directors and Independent Board Members within the framework of the determined principles,
7. Discussion and resolution of the Board of Directors' proposal, prepared within the framework of the Company's dividend distribution policy, regarding the appropriation of the 2025 profit and profit distribution,
8. Informing shareholders about (i) the "Remuneration Policy for Board Members and Senior Executives" and (ii) the benefits provided to board members and senior executives during the year 2025,
9. Determination of the annual and/or monthly remuneration of the members of the Board of Directors,
10. Submission for the approval of the General Assembly of the members of the Board of Directors elected due to vacancies arising on the Board of Directors pursuant to Article 363 of the Turkish Commercial Code,
11. Discussion and resolution of the proposal of the Board of Directors regarding the selection of the independent external audit firm,
12. Informing shareholders about the donations made by the Company during the 2025 financial year and discussion and resolution of the upper limit for donations to be made during the 2026 financial year,
13. Informing shareholders about the guarantees, pledges, mortgages, and sureties provided by the Company in favor of third parties during 2025, as well as the income or benefits obtained therefrom,
14. Informing shareholders about transactions carried out with related parties during the year 2025,
15. Informing shareholders about transactions carried out during 2025 by controlling shareholders, members of the Board of Directors, executives with administrative responsibility, and their spouses and relatives by blood or marriage up to the second degree,
16. Granting permission to the members of the Board of Directors pursuant to Articles 395/1 and 396 of the Turkish Commercial Code,
17. Wishes and opinions,
18. Closing,

6) Dividend Distribution

Article 23 of the Company's Articles of Association, titled "Determination and Distribution of Profit," sets out the following principles regarding the determination and distribution of profit:

The method and timing of profit distribution shall be determined by the General Assembly based on the proposal of the Board of Directors, However, the distribution period of the year-end dividends shall not exceed the period specified in the communiqués of the Capital Markets Board,

Dividends shall be distributed equally to all existing shares as of the distribution date, regardless of their issuance and acquisition dates, No dividend distribution was made during the period,

According to the Company's financial statements for the accounting period from 1 January 2025 to 31 December 2025, which were prepared in accordance with the Capital Markets Board's Communiqué on Principles of Financial Reporting in Capital Markets (II-14,1) and independently audited by Eren Bağımsız Denetim A,Ş,, the Company recorded a loss in the amount of TRY 3,115,210,956 (TRY 254,242,280 according to the records prepared in accordance with the Tax Procedure Law), As there is no distributable profit for the relevant period, no dividend distribution will be made, Accordingly, it has been resolved that the said loss be added to prior years' losses and that this matter be submitted for the approval of the shareholders at the Company's first General Assembly Meeting, https://kap.org.tr/tr/Bildirim/1579005

7) The Sector in Which the Company Operates and Its Position Within the Sector

As Banvit, we began our operations in 1968 as a small-scale feed producer, In 1984, we entered the poultry meat production business, At that time, we became the first company in Türkiye to offer cleaned, fresh poultry meat to consumers in packaged and branded form, thereby assuming a pioneering role in our industry, In 2001, we commissioned our Further Processing Facilities, expanding our production portfolio, Through these investments, we began offering consumers convenient, ready-to-cook and ready-to-eat products such as nuggets, döner, kebabs, meatballs, and delicatessen products, In addition to our main production facilities in Bandırma, we expanded our operations by opening additional production facilities in İzmir and, in subsequent years, in Elazığ, enabling us to serve millions of consumers both domestically and internationally,

Today, Banvit is pleased to be among Türkiye's leading food companies, providing daily service to its customers with a broad product portfolio, In addition to the Banvit master brand, we continue to serve different customer segments and needs through our sub-brands,

While implementing new initiatives with the vision of strengthening our pioneering position in the sector, we act in line with our mission to creatively, qualitatively, and deliciously meet consumer and customer expectations; to contribute to providing reliable animal protein produced under hygienic conditions that meet nutritional needs; and to remain sensitive to environmental sustainability, animal welfare, and employee well-being,

8) Incentives

The Company holds several rights and incentives that are available to all entities meeting the legal criteria, regardless of their sector of activity, These include:

- Investment Incentive Certificates
- Inward Processing Authorization Certificates (Exemption from Customs Duty, VAT exemption, corporate tax incentives, and employer's share of social security premium support)
- Social Security Institution (SSI) Incentives
- Energy Support

9) The Development of the Company

The Company's finished broiler meat production during the first nine months of 2026 decreased by 9.2% compared to the same period of the previous year. Production of further processed products also declined by 6.4% during the same period.

Approximately 8.8% of the total poultry and further processed products produced during the first three quarters of 2026 was exported.

Domestic sales decreased by 7.6% in the aggregate of the first three quarters of 2026 (Q1–Q3) compared to the corresponding period of the previous year, while exports declined by 18.0%.

Approximately 11% of the total poultry and further processed products produced during the third quarter of 2026 (Q3) was exported.

The Company's finished broiler meat production in the third quarter of 2026 increased by 10.4% compared to the second quarter of 2026. Production of further processed products also increased by 23.1% over the same period.

While the Company's domestic sales in the third quarter of 2026 (Q3) increased by 3.5% compared to the second quarter of 2026 (Q2), exports recorded a substantial increase of 153% during the same period. The primary reason for this increase in exports was the lifting of export restrictions as of early July and the transition to a quota-based system.

General poultry production statistics in Türkiye are updated by TURKSTAT (Turkish Statistical Institute). Data for a given month becomes available approximately two months after the relevant reporting period.

According to TURKSTAT data, during the period from January to August 2026, the quantity of broiler meat supplied to the domestic market increased by 5.2% compared to the same period of the previous year, while export volumes decreased by 17.7%.

Total production increased by 1.4% during the January-August 2026 period compared to the corresponding period of 2025. Total broiler meat production in Türkiye amounted to 1,859 thousand tonnes during the relevant period of 2026, compared to 1,833 thousand tonnes in the same period of 2025.

10) Developments in Sales

On a domestic market basis, comparing the **third quarter of 2026 (Q3 2026)** with the **third quarter of 2025 (Q3 2025)**, net revenue generated from **finished broiler meat** and **processed products (ready-to-eat products and delicatessen products)** increased by **23.1%** in the third quarter of 2026 compared to the corresponding period of the previous year.

The breakdown of the change in net revenue by product category is presented below:

Product	**(%)**
Total Processed Chicken	25,1
Total Further Processed Products (Ready-to-Eat& Delicatessen)	18,6
2025/2026 Net Sales Revenue Change	23,1

On a domestic market basis, comparing the **third quarter of 2026 (Q3 2026)** with the **second quarter of 2026 (Q2 2026)**, net revenue generated from **finished broiler meat** and **processed products (ready-to-eat products and delicatessen products)** increased by **7.5%** in the third quarter of 2026.

The breakdown of the change in net revenue by product category is presented below:

Product	**(%)**
Total Processed Chicken	3,3
Total Further Processed Products (Ready-to-Eat&Delicatessen)	18,6
2026 Q1/2026 Q2 Net Sales Revenue Change	7,5

On an export basis, comparing the **third quarter of 2026 (Q3 2026)** with the **third quarter of 2025 (Q3 2025)**, net revenue generated from **finished broiler meat** and **processed products (ready-to-eat products and delicatessen products)** increased by **7.2%** in the third quarter of 2026 compared to the corresponding period of the previous year.

The breakdown of the change in net revenue by product category is presented below:

Product	**(%)**
Total Processed Chicken	5,00
Total Further Processed Products (Ready-to-Eat&Delicatessen)	10,9
2025/2026 Net Sales Revenue Change	7,2

On an export basis, comparing the **third quarter of 2026 (Q3 2026)** with the **second quarter of 2026 (Q2 2026)**, net revenue generated from **finished broiler meat** and **processed products (ready-to-eat products and delicatessen products)** increased by **208.7%** in the third quarter of 2026 compared to the second quarter of 2026.
The breakdown of the change in net revenue by product category is presented below:

Product	**(%)**
Total Processed Chicken	1010,3
Total Further Processed Products (Ready-to-Eat & Delicatessen)	40,8
2026 Q1/2026 Q2 Net Sales Revenue Change	208,7

All of the above assessments have been made based on nominal values,

F. Risk Management

1) Corporate Risk Management

In order to systematically and comprehensively identify, assess, control, and monitor the risks and opportunities that may affect the Company's assets, reputation, and profitability, as well as to define responsible parties and develop action plans to mitigate their potential impacts, the Risk and Internal Control Department has established a risk map and risk management policies,

These policies provide guidance on ensuring that risks are managed at the highest possible standards within the Company, They cover principles related to support and positioning, risk identification, prioritization, improvement, reporting, monitoring/supervision, and communication regarding risk management,

In line with applicable regulations and internal directives, the Company continuously monitors and manages its risks to ensure that critical risks remain within the defined tolerance levels, Furthermore, the Company develops and implements appropriate risk mitigation strategies to safeguard its operations and maintain sustainable business performance.

2) Early Risk Detection Committee

The purpose of the Committee is to ensure, within the framework of applicable regulations and legal requirements, the early detection of risks that may endanger the existence, development, and continuity of the Company, the implementation of necessary measures related to the identified risks, and the effective management of such risks,

The Committee meetings are held once every two months to enable the Committee to perform its duties effectively, Following each meeting, a written report on the Committee's activities, together with a summary of the meeting minutes, is submitted to the Board of Directors,

G. Other Matters

1) Organizational Structure- Branches as of Sep 30, 2026

BRANCH	LOCATION	DISTRIBUTION CENTER	LOCATION
Ankara Branch	Ankara	Chicken Slaughterhouse	Balıkesir
Esenboğa Branch	Ankara	FPP	Balıkesir
Adana Branch	Adana	Bandirma Hatchery	Balıkesir
Ayazağa Branch	İstanbul	Taşköy Hatchery	Balıkesir
Kadıköy Branch	İstanbul	Bandirma Feedmill	Balıkesir
Kartal Branch	İstanbul	Bandırma Rendering	Balıkesir
Hadımköy Branch	İstanbul	Bandırma WWT	Balıkesir
Pınarbaşı Branch	İzmir	Chicken Slaughterhouse	İzmir
Kayseri Branch	Kayseri	İzmir Feedmill	İzmir
Muğla Branch	Muğla	İzmir Rendering	İzmir
Fethiye Branch	Muğla	Chicken Slaughterhouse	Elazığ
Bodrum Branch	Muğla	Hatchery	Elazığ
Antalya Branch	Antalya	Elazig Feedmill	Elazığ
Bursa Branch	Bursa	Elazig Rendering	Elazığ
Samsun Branch	Samsun	Breeders Farm	Elazığ
Trakya Şube	Kırklareli	Hicri Ercili Warehouse	Balıkesir
Söke Branch	Aydın	Özuğur Warehouse	Elazığ
Sarniç Branch	İzmir	Hitit Warehouse	İzmir
Konya Branch	Konya	Irmak Warehouse	İzmir
		Kapçak Warehouse	Balıkesir

2) Sustainability Principles

Environmental, social, and corporate governance activities that fall within the scope of the Sustainability Principles Compliance Framework are carried out by our Company, The implementation of sustainability principles is based on a voluntary approach, and the impacts of these principles on environmental and social risk management are evaluated by our Company, A summary of sustainability activities is provided in the Appendix,

In accordance with the Turkish Sustainability Reporting Standards (“TSRS”), companies whose shares are traded on Borsa İstanbul are required to prepare sustainability reports for financial periods beginning on or after 1 January 2024, Accordingly, all sustainability activities carried out during the year 2024 are required to be reported within the year 2025, Likewise, sustainability activities conducted during the year 2025 must be reported within the year 2026.

3) Significant Developments

No matter exists

4) Significant Developments Subsequent to the Reporting Period

No such matter exists,

H. Investor Relations

INVESTOR RELATIONS

BANVİT BANDIRMA VİTAMİNLİ YEM SANAYİ ANONİM ŞİRKETİ shares have been traded on Borsa İstanbul since November 27, 1992,

The Company's issued capital amounts to ₺100,023,579 consisting of 100,023,579 shares, each with a nominal value of ₺1,

Listed on Borsa İstanbul A,Ş, under the BANVT ticker, the Company had a market capitalization of ₺12,753,006,323 as of Sep 30, 2026,

News and financial information regarding Banvit Bandırma Vitaminli Yem Sanayi Anonim Şirketi can be accessed via the Company's official website or obtained from the Investor Relations Department,

E-mail: Banvit.ir@brf.com
Web: www.banvit.com

2026	CLOSING PRICE (TRY)	HIGHEST PRICE (TRY)	LOWEST PRICE (TRY)
BANVT	130,30	130,80	127,10

Disclosure on Market Data and Forward-Looking Statements

This report has been prepared in accordance with applicable regulations for informational purposes only and does not constitute a basis for any investment decision, Industry, market, and competitive environment data included in this report have been sourced from official or third-party sources, While the Company believes that these sources are reliable, it has not independently verified the accuracy of the information, The Company, its Management, employees, or other relevant parties cannot be held liable for any direct or indirect losses or damages arising from the use of this information, This report contains forward-looking statements, which are subject to risks, uncertainties, and other important factors that are beyond or only partially within the Company's control, These factors may cause the Company's future results, performance, or achievements to differ materially from those expressed in the forward-looking statements, The forward-looking statements in this report reflect the Company's views as of the date of preparation, The Company, its Management, employees, or other relevant parties cannot be held liable for any direct or indirect losses or damages arising from the use of these statements, As of the publication date, all information presented in this report is believed to be accurate, however, the Company accepts no responsibility for errors that may occur during the writing, printing, or publishing process,